New developments in paraneoplastic neurological diseases;Neues bei paraneoplastischen Syndromen in der Neurologie

Aktuelle Neurologie

Volumn 39, Issue 2, 2012, Pages 60-73

  Leypoldt, F ^a   Wandinger, K P ^a,b   Voltz, R ^c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Institute of Experimental Immunology   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

encephalitis; paraneoplastic diseases; tumours

Indexed keywords

ARTICLE; DISEASE CLASSIFICATION; PARANEOPLASTIC NEUROPATHY; PATHOPHYSIOLOGY;

EID: 84858448880     PISSN: 03024350     EISSN: 14389428     Source Type: Journal    
DOI: 10.1055/s-0032-1304305     Document Type: Article

References (110)

1. Graus F, Delattre J Y, Antoine J C et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatr: 2004; 75 1135 1140 (Pubitemid 39005770)
2. Graus F, Cordon-Cardo C, Posner J. Neuronal antinuclear antibody in sensory neuronopathy from lung cancer. Neurology: 1985; 35 538 543 (Pubitemid 15085073)
3. Giometto B, Grisold W, Vitaliani R et al. Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch Neurol: 2010; 67 330 335
4. van Oosterhout A G, van de Pol M, Velde ten G P et al. Neurologic disorders in 203 consecutive patients with small cell lung cancer. Results of a longitudinal study. Cancer: 1996; 77 1434 1441 (Pubitemid 26105377)
5. Rosenfeld M R, Dalmau J. Anti-NMDA-Receptor Encephalitis and Other Synaptic Autoimmune Disorders. Curr Treat Options Neurol: 2011
6. Bataller L, Kleopa K A, Wu G F et al. Autoimmune limbic encephalitis in 39 patients: immunophenotypes and outcomes. J Neurol Neurosurg Psychiatr: 2007; 78 381 385 (Pubitemid 46580546)
7. Gultekin S H, Rosenfeld M R, Voltz R et al. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain: 2000; 123 Pt 7 1481 1494 (Pubitemid 30420947)
8. Cross S A, Salomao D R, Parisi J E et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol: 2003; 54 38 50 (Pubitemid 36764980)
9. Honnorat J, Antoine J, Derrington E et al. Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry: 1996; 61 270 278 (Pubitemid 26293722)
10. Kinirons P, Fulton A, Keoghan M et al. Paraneoplastic limbic encephalitis (PLE) and chorea associated with CRMP-5 neuronal antibody. Neurology: 2003; 61 1623 1624 (Pubitemid 37505596)
11. Dalmau J, Graus F, Villarejo A et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain: 2004; 127 1831 1844 (Pubitemid 39061559)
12. Hoffmann L A, Jarius S, Pellkofer H L et al. Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes: 22 newly diagnosed patients and review of previous cases. J Neurol Neurosurg Psychiatr: 2008; 79 767 773 (Pubitemid 351914721)
13. Pittock S J, Lucchinetti C F, Parisi J E et al. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol: 2005; 58 96 107 (Pubitemid 40962465)
14. Saiz A, Bruna J, Stourac P et al. Anti-Hu-associated brainstem encephalitis. J Neurol Neurosurg Psychiatr: 2009; 80 404 407
15. Lucchinetti C, Kimmel D, Lennon V. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology: 1998; 50 652 657
16. Prüss H, Dalmau J, Harms L et al. Retrospective analysis of NMDA receptor antibodies in encephalitis of unknown origin. Neurology: 2010; 75 1735 1739
17. Granerod J, Ambrose H E, Davies N W et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis: 2010; 10 835 844
18. Dalmau J, Lancaster E, Martinez-Hernandez E et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol: 2011; 10 63 74
19. Irani S R, Bera K, Waters P et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain: 2010; 133 1655 1667
20. Kleinig T J, Thompson P D, Matar W et al. The distinctive movement disorder of ovarian teratoma-associated encephalitis. Mov Disord: 2008; 23 1256 1261
21. Dale R C, Irani S R, Brilot F et al. N-methyl-D-aspartate receptor antibodies in pediatric dyskinetic encephalitis lethargica. Ann Neurol: 2009; 66 704 709
22. Zandi M S, Irani S R, Follows G et al. Limbic encephalitis associated with antibodies to the NMDA receptor in Hodgkin lymphoma. Neurology: 2009; 73 2039 2040
23. Dalmau J, Gleichman A J, Hughes E G et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol: 2008; 7 1091 1098
24. Kruer M C, Koch T K, Bourdette D N et al. NMDA receptor encephalitis mimicking seronegative neuromyelitis optica. Neurology: 2010; 74 1473 1475
25. Leypoldt F, Buchert R, Kleiter I et al. Anti-NMDA receptor encephalitis exhibits frontotemporo-occipital gradient of glucose metabolism. JNNP submitted
26. Lai M, Hughes E G, Peng X et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol: 2009; 65 424 434
27. Bataller L, Galiano R, Garca-Escrig M et al. Reversible paraneoplastic limbic encephalitis associated with antibodies to the AMPA receptor. Neurology: 2010; 74 265 267
28. Lai M, Huijbers MG M, Lancaster E et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol: 2010; 9 776 785
29. Lancaster E, Huijbers MG M, Bar V et al. Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol: 2011; 69 303 311
30. Irani S R, Alexander S, Waters P et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis. Morvan's syndrome and acquired neuromyotonia Brain: 2010
31. Lancaster E, Lai M, Peng X et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol: 2009
32. Boronat A, Sabater L, Saiz A et al. GABAB receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology: 2011; 76 795 800
33. Irani S R, Michell A W, Lang B et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol: 2011; 69 892 900
34. Vincent A, Buckley C, Schott J M et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain: 2004; 127 701 712 (Pubitemid 38295483)
35. Jarius S, Hoffmann L, Clover L et al. CSF findings in patients with voltage gated potassium channel antibody associated limbic encephalitis. J Neurol Sci: 2008; 268 74 77
36. Graus F, Boronat A, Xifr X et al. The expanding clinical profile of anti-AMPA receptor encephalitis. Neurology: 2010; 74 857 859
37. Choi K-D, Kim J S, Park S-H et al. Cerebellar hypermetabolism in paraneoplastic cerebellar degeneration. J Neurol Neurosurg Psychiatr: 2006; 77 525 528
38. Mason W P, Graus F, Lang B et al. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain: 1997; 120 Pt 8 1279 1300 (Pubitemid 27344700)
39. Peterson K, Rosenblum M, Kotanides H et al. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology: 1992; 42 1931 1937
40. Rojas-Marcos I, Rousseau A, Keime-Guibert F et al. Spectrum of paraneoplastic neurologic disorders in women with breast and gynecologic cancer. Medicine (Baltimore): 2003; 82 216 223 (Pubitemid 36578710)
41. McKeon A, Tracy J A, Pittock S J et al. Purkinje cell cytoplasmic autoantibody type 1 accompaniments: the cerebellum and beyond. Arch Neurol: 2011; 68 1282 1289
42. Bataller L, Graus F, Saiz A et al. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain: 2001; 124 437 443 (Pubitemid 32142415)
43. Bataller L, Rosenfeld M R, Graus F et al. Autoantigen diversity in the opsoclonus-myoclonus syndrome. Ann Neurol: 2003; 53 347 353 (Pubitemid 36258638)
44. Kurian M, Lalive P H, Dalmau J. Opsoclonus-myoclonus syndrome in anti-N-methyl-D-aspartate receptor encephalitis. Arch Neurol: 2010; 67 118 121
45. Smith J H, Dhamija R, Moseley B D et al. N-methyl-D-aspartate receptor autoimmune encephalitis presenting with opsoclonus-myoclonus: treatment response to plasmapheresis. Arch Neurol: 2011; 68 1069 1072
46. Mas N, Saiz A, Leite M I et al. Antiglycine-receptor encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatr: 2010
47. Turner M R, Irani S R, Leite M I et al. Progressive encephalomyelitis with rigidity and myoclonus: glycine and NMDA receptor antibodies. Neurology: 2011; 77 439 443
48. Katz J D, Ropper A H. Progressive necrotic myelopathy: clinical course in 9 patients. Arch Neurol: 2000; 57 355 361 (Pubitemid 30140522)
49. Pittock S J, Lennon V A. Aquaporin-4 autoantibodies in a paraneoplastic context. Arch Neurol: 2008; 65 629 632 (Pubitemid 351679657)
50. Panzer J, Dalmau J. Movement disorders in paraneoplastic and autoimmune disease. Curr Opin Neurol: 2011; 24 346 353
51. Grant R, Graus F. Paraneoplastic movement disorders. Mov Disord: 2009; 24 1715 1724
52. Hiyama T Y, Matsuda S, Fujikawa A et al. Autoimmunity to the sodium-level sensor in the brain causes essential hypernatremia. Neuron: 2010; 66 508 522
53. Camdessanch J-P, Antoine J-C, Honnorat J et al. Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies. A clinical and electrophysiological study of 20 patients. Brain: 2002; 125 166 175 (Pubitemid 34084046)
54. Vallat J M, De Mascarel H A, Bordessoule D et al. Non-Hodgkin malignant lymphomas and peripheral neuropathies - 13 cases. Brain: 1995; 118 Pt 5 1233 1245
55. Oh S J. Paraneoplastic vasculitis of the peripheral nervous system. Neurol Clin: 1997; 15 849 863 (Pubitemid 28009352)
56. Leypoldt F, Friese M A, Böhm J et al. Multiple enlarged nerves on neurosonography: An unusual paraneoplastic case. Muscle Nerve: 2011; 43 756 757
57. Camdessanch J-P, Jousserand G, Ferraud K et al. The pattern and diagnostic criteria of sensory neuronopathy: a case-control study. Brain: 2009; 132 1723 1733
58. Antoine J C, Honnorat J, Camdessanch J P et al. Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann Neurol: 2001; 49 214 221 (Pubitemid 32157997)
59. Graus F, Keime-Guibert F, Ree R et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain: 2001; 124 1138 1148 (Pubitemid 32510382)
60. Lee H R, Lennon V A, Camilleri M et al. Paraneoplastic gastrointestinal motor dysfunction: clinical and laboratory characteristics. Am J Gastroenterol: 2001; 96 373 379
61. McKeon A, Lennon V A, Lachance D H et al. Ganglionic acetylcholine receptor autoantibody: oncological, neurological, and serological accompaniments. Arch Neurol: 2009; 66 735 741
62. Chamberlain J L, Pittock S J, Oprescu A-M et al. Peripherin-IgG association with neurologic and endocrine autoimmunity. Journal of autoimmunity: 2010
63. Stich O, Kleer B, Rauer S. Absence of paraneoplastic antineuronal antibodies in sera of 145 patients with motor neuron disease. J Neurol Neurosurg Psychiatr: 2007; 78 883 885 (Pubitemid 47204599)
64. Younger D S. Motor neuron disease and malignancy. Muscle Nerve: 2000; 23 658 660 (Pubitemid 30256596)
65. Briani C, Vitaliani R, Grisold W et al. Spectrum of paraneoplastic disease associated with lymphoma. Neurology: 2011; 76 705 710
66. Hart I K, Maddison P, Newsom-Davis J et al. Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain: 2002; 125 1887 1895
67. Loukaides P, Schiza N, Pettingill P et al. Morvan's syndrome associated with antibodies to multiple components of the voltage-gated potassium channel complex. J Neurol Sci: 2011
68. Payne M, Bradbury P, Lang B et al. Prospective Study into the Incidence of Lambert Eaton Myasthenic Syndrome in Small Cell Lung Cancer. J Thorac Oncol: 2009; 5 34 38
69. Monstad S E, Knudsen A, Salvesen H B et al. Onconeural antibodies in sera from patients with various types of tumours. Cancer Immunol Immunother: 2009; 58 1795 1800
70. Graus F, Dalmou J, Rene R et al. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol: 1997; 15 2866 2872 (Pubitemid 27330014)
71. Honnorat J, Cartalat-Carel S, Ricard D et al. Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatr: 2009; 80 412 416
72. Kazarian M, Calbo J, Proost N et al. Immune response in lung cancer mouse model mimics human anti-Hu reactivity. J Neuroimmunol: 2009; 217 38 45
73. de Graaf M T, de Beukelaar JW K, Haasnoot G W et al. HLA-DQ2(+) individuals are susceptible to Hu-Ab associated paraneoplastic neurological syndromes. J Neuroimmunol: 2010
74. Dalmau J, Graus F, Cheung N et al. Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. Cancer: 1995; 75 99 109
75. Greenlee J, Parks T, Jaeckle K. Type IIa ("anti-Huo") antineuronal antibodies produce destruction of rat cerebellar granule neurons in vitro. Neurology: 1993; 43 2049 2054 (Pubitemid 23318878)
76. Hormigo A, Lieberman F. Nuclear localization of anti-Hu antibody is not associated with in vitro cytotoxicity. J Neuroimmunol: 1994; 55 205 212
77. Verschuuren J J, Dalmau J, Hoard R et al. Paraneoplastic anti-Hu serum: studies on human tumor cell lines. J Neuroimmunol: 1997; 79 202 210 (Pubitemid 27502039)
78. Sillevis Smitt P, Manley G, Posner J. Immunization with the paraneoplastic encephalomyelitis antigen HuD does not cause neurologic disease in mice. Neurology: 1995; 45 1873 1878 (Pubitemid 27122961)
79. Tanaka M, Tanaka K, Onodera O et al. Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody. 1. Mouse strains bearing different MHC molecules produce antibodies on immunization with recombinant Yo protein, but do not cause Purkinje cell loss. Clin Neurol Neurosurg: 1995; 97 95 100
80. Voltz R, Dalmau J, Posner J B et al. T-cell receptor analysis in anti-Hu associated paraneoplastic encephalomyelitis. Neurology: 1998; 51 1146 1150 (Pubitemid 28473416)
81. Albert M L, Darnell J C, Bender A et al. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med: 1998; 4 1321 1324 (Pubitemid 28512116)
82. Benyahia B, Liblau R, Merle-Bral H et al. Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies. Ann Neurol: 1999; 45 162 167 (Pubitemid 29072361)
83. Pellkofer H, Schubart A S, Höftberger R et al. Modelling paraneoplastic CNS disease: T-cells specific for the onconeuronal antigen PNMA1 mediate autoimmune encephalomyelitis in the rat. Brain: 2004; 127 1822 1830 (Pubitemid 39061558)
84. DeLuca I, Blachre N E, Santomasso B et al. Tolerance to the neuron-specific paraneoplastic HuD antigen. PLoS ONE: 2009; 4 e5739
85. de Beukelaar J W, Verjans G M, van Norden Y et al. No evidence for circulating HuD-specific CD8+ T cells in patients with paraneoplastic neurological syndromes and Hu antibodies. Cancer Immunol Immunother: 2007; 56 1501 1506 (Pubitemid 47024715)
86. Roberts W K, Deluca I J, Thomas A et al. Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells. J Clin Invest: 2009; 119 2042 2051
87. Tani T, Tanaka K, Idezuka J et al. Regulatory T cells in paraneoplastic neurological syndromes. J Neuroimmunol: 2008; 196 166 169
88. Hughes E G, Peng X, Gleichman A J et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci: 2010; 30 5866 5875
89. Tüzün E, Zhou L, Baehring J M et al. Evidence for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated with ovarian teratoma. Acta Neuropathol: 2009; 118 737 743
90. Martinez-Hernandez E, Horvath J, Shiloh-Malawsky Y et al. Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis. Neurology: 2011; 77 589 593
91. de Lange R, Dimoudis N, Weidle U H. Identification of genes associated with enhanced metastasis of a large cell lung carcinoma cell line. Anticancer Res: 2003; 23 187 194 (Pubitemid 36358516)
92. Hofmann C, Baur M-O, Schroten H. Anti-NMDA receptor encephalitis after TdaP-IPV booster vaccination: cause or coincidence? J Neurol: 2011; 258 500 501
93. Psimaras D, Carpentier A, Rossi C. CSF study in paraneoplastic syndromes. J Neurol Neurosurg Psychiatr: 2009
94. Wandinger KP L, Klingbeil C, Gneiss C et al. New serological markers for the differential diagnosis of autoimmune limbic encephalitis. J Lab Med: 2011; 35 329 342
95. Sabater L, Titulaer M, Saiz A et al. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology: 2008; 70 924 928 (Pubitemid 351430756)
96. Titulaer M J, Klooster R, Potman M et al. SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival. J Clin Oncol: 2009; 27 4260 4267
97. Hadjivassiliou M, Alder S J, Van Beek EJ R et al. PET scan in clinically suspected paraneoplastic neurological syndromes: a 6-year prospective study in a regional neuroscience unit. Acta Neurologica Scandinavica: 2009; 119 186 193
98. Titulaer M J, Soffietti R, Dalmau J et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol: 2011; 18 19 e3
99. Titulaer M J, Wirtz P W, Willems LN A et al. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol: 2008; 26 4276 4281
100. Candler P, Hart P, Barnett M et al. A follow up study of patients with paraneoplastic neurological disease in the United Kingdom. J Neurol Neurosurg Psychiatry: 2004; 75 1411 1415
101. Sillevis Smitt P, Grefkens J, De Leeuw B et al. Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol: 2002; 249 745 753 (Pubitemid 34651757)
102. Keime-Guibert F, Graus F, Fleury A et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatr: 2000; 68 479 482 (Pubitemid 30248748)
103. Shamsili S, de Beukelaar J, Gratama J W et al. An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol: 2006; 253 16 20 (Pubitemid 43157382)
104. Keogh M, Sedehizadeh S, Maddison P. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev: 2011; 2 CD003279
105. Dalakas M C, Koffman B, Fujii M et al. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology: 2001; 56 323 327 (Pubitemid 32144142)
106. Espandar L, O'Brien S, Thirkill C et al. Successful treatment of cancer-associated retinopathy with alemtuzumab. J Neurooncol: 2007; 83 295 302 (Pubitemid 46952241)
107. Stark E, Wurster U, Patzold U et al. Immunological and clinical response to immunosuppressive treatment in paraneoplastic cerebellar degeneration. Arch Neurol: 1995; 52 814 818
108. Cher L, Hochberg F, Teruya J et al. Therapy for paraneoplastic neurologic syndromes in six patients with protein A column immunoadsorption. Cancer: 1995; 75 1678 1683
109. Uchuya M, Graus F, Vega F et al. Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. J Neurol Neurosurg Psychiatry: 1996; 60 388 392 (Pubitemid 26118745)
110. Cree BA C, Lamb S, Morgan K et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology: 2005; 64 1270 1272